Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isracann Biosciences Inc ISCNF

Healthcare Drug Manufacturers - Major Cannabis
Isracann Biosciences Inc. is a Canada-based cannabis company. The principal business focus of the Company is medical cannabis cultivation and distribution to provide products to the Israeli medical cannabis market, and to develop and validate Natural Health Products (NHP), through the Company’s operating subsidiaries. The Company's segments include Head Office, Medical Cannabis and Natural... see more

GREY:ISCNF - Post Discussion

Isracann Biosciences Inc > Broken promises by CEO, Phil, and management
View:
Post by Farlo2020 on Nov 28, 2022 7:21pm

Broken promises by CEO, Phil, and management

"This is the first step in delivering on our commitment to our shareholders of having products at market in Q4 2022".

the above from Sept 1/22 news release. Nothing from these jokers ... and share price sitting at $0.015. 

your people in Israel r u stupid and blind ? You are the majority share holders, control this company. Get rid of this ceo and management 

Be the first to comment on this post
Isracann Biosciences Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities